Association of Sacubitril/Valsartan vs Valsartan With Blood Pressure Changes and Symptomatic Hypotension: the PARAGLIDE-HF Trial
Journal of Cardiac Failure · 2024
DOI: 10.1016/j.cardfail.2024.04.030 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cardiac Failure, 2024. Verfasst von Marat Fudim und 16 weiteren Autor:innen. Beteiligte Einrichtung: Duke Clinical Research Institute, Durham, NC, USA. Electronic address: marat.fudim@duke.edu. Hauptthemen laut MEDLINE: Aminobutyrates, Angiotensin Receptor Antagonists, Biphenyl Compounds, Blood Pressure. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 16 Literaturangaben. Gefördert von: Novartis Pharmaceuticals Corp.
Abstract (Originalsprache)
BACKGROUND: In PARAGLIDE-HF, in patients with ejection fraction (EF) > 40%, stabilized after worsening heart failure (WHF), sacubitril/valsartan led to greater reduction in plasma NT-proBNP levels and was associated with clinical benefit compared to valsartan alone, despite more symptomatic hypotension (SH). Concern about SH may be limiting the use of sacubitril/valsartan in appropriate patients. METHODS: We characterized patients by the occurrence of SH (investigator-reported) after randomization to either sacubitril/valsartan or valsartan. A key trial inclusion criterion was systolic blood pressure (SBP) ≥ 100 mmHg for the preceding 6 hours and no SH. We also compared outcomes based on baseline SBP stratified by the median blood pressure. The primary endpoint was time-averaged proportional change in NT-proBNP levels from baseline through weeks 4 and 8. A secondary hierarchical outcome (win ratio) consisted of: (1) cardiovascular death; (2) hospitalizations due to HF; (3) urgent HF visits; and (4) change in NT-proBNP levels. RESULTS: Among 466 randomized patients, 92 (19.7%) experienced SH (sacubitril/valsartan, n = 56 [24.0%]; valsartan, n = 36 [15.5%]; P = 0.020). The median time to the first SH event was similar between treatment arms (18 days vs 15 days, respectively; P = 0.42) as was the proportion of first SH events classified as serious by investigators. Patients who experienced SH with sacubitril/valsartan were more likely to be white (OR 1.87 [95% CI: 0.31, 11.15]), to have a lower baseline SBP (per 10 mmHg increase, OR 0.68 [95% CI: 0.55, 0.85]), or to have a left ventricular ejection fraction (LVEF) of > 60% (OR 2.21 [95% CI: 1.05, 4.65]). Time-averaged change in NT-proBNP levels did not differ between patients with baseline SBP ≥ 128 mmHg vs SBP 40% stabilized after WHF, incident SH was more common with sacubitril/valsartan compared with valsartan. SH was associated with lower baseline SBP, being white, and having higher LVEF. Treatment benefits with sacubitril/valsartan may be more pronounced in patients with higher baseline SBP and lower LVEF (≤ 60%). (Funded by Novartis Pharmaceutical Corporation; ClinicalTrials.gov number, NCT03988634.).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Duke Clinical Research Institute, Durham, NC, USA. Electronic address: marat.fudim@duke.edu.
- Duke Clinical Research Institute, Durham, NC, USA.
- Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
- Department of Cardiology, Université de Sherbrooke, Sherbrooke, Quebec, Canada.
- Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
- Division of Cardiology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Förderung
- Novartis Pharmaceuticals Corp
Zitieren
APA
Fudim, M., Cyr, D. D., Ward, J. H., Hernandez, A. F., Lepage, S., Morrow, D. A., Sharma, K., Claggett, B. L., Starling, R. C., Velazquez, E. J., Williamson, K. M., Desai, A. S., Zieroth, S., Solomon, S. D., Braunwald, E., Mentz, R. J., & PARAGLIDE-HF investigators (2024). Association of Sacubitril/Valsartan vs Valsartan With Blood Pressure Changes and Symptomatic Hypotension: the PARAGLIDE-HF Trial. Journal of Cardiac Failure. https://doi.org/10.1016/j.cardfail.2024.04.030
Vancouver
Fudim M, Cyr DD, Ward JH, Hernandez AF, Lepage S, Morrow DA, et al. Association of Sacubitril/Valsartan vs Valsartan With Blood Pressure Changes and Symptomatic Hypotension: the PARAGLIDE-HF Trial. Journal of Cardiac Failure. 2024. doi:10.1016/j.cardfail.2024.04.030
BibTeX
@article{Fudim2024,
author = {Fudim, Marat and Cyr, Derek D and Ward, Jonathan H and Hernandez, Adrian F and Lepage, Serge and Morrow, David A and Sharma, Kavita and Claggett, Brian L and Starling, Randall C and Velazquez, Eric J and Williamson, Kristin M and Desai, Akshay S and Zieroth, Shelley and Solomon, Scott D and Braunwald, Eugene and Mentz, Robert J and PARAGLIDE-HF investigators, PARAGLIDE-HF investigators},
title = {Association of Sacubitril/Valsartan vs Valsartan With Blood Pressure Changes and Symptomatic Hypotension: the PARAGLIDE-HF Trial},
journal = {Journal of Cardiac Failure},
year = {2024},
doi = {10.1016/j.cardfail.2024.04.030}
}
EUVIMED